Dylann Cohn-Emery

3 weeks ago | targetedonc.com | Dylann Cohn-Emery

AlloHeme, a highly sensitive, noninvasive blood test, demonstrated superior sensitivity compared with traditional methods in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in detecting a risk of relapse posttransplant.1At the 2025 Tandem Meetings, Monzr M. Al Malki, MD, presented the results for AlloHeme,which uses next-generation sequencing (NGS) to monitor chimerism levels for patients after transplant.

2 months ago | targetedonc.com | Dylann Cohn-Emery

Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting the efficacy of daratumumab (Darzalex) in combination therapies, chimeric antigen receptor (CAR) T-cell therapy’s high minimal residual disease (MRD)–negativity rates and extended remissions, and what these advancements mean for treatment in 2025.

2 months ago | cancernetwork.com | Dylann Cohn-Emery

Data presented at the 2025 Tandem Meeting from a phase 2 study indicate that ruxolitinib (Jakafi), when combined with standard graft-vs-host disease (GVHD) prophylaxis, significantly lowers the risk of developing acute and chronic GVHD without sacrificing survival benefit in patients with myelofibrosis undergoing hematopoietic cell transplantation (HCT).

2 months ago | targetedonc.com | Dylann Cohn-Emery

Adding ruxolitinib (Jakafi) to standard graft-vs-host disease (GVHD) prophylaxis reduced incidence of acute and chronic GVHD while maintaining survival rates in patients with myelofibrosis undergoing hematopoietic cell transplantation (HCT), according to data presented at the 2025 Transplantation & Cellular Therapy Meetings.1 The phase 2 prospective study (NCT04384692) conducted at Fred Hutchinson Cancer Center showed grade II to IV acute GVHD occurred in 32% of patients receiving...

2 months ago | targetedonc.com | Dylann Cohn-Emery

Edward S. Kim, MD, MBA, discussed the impact of recent wildfires on patients with cancer at City of Hope in Duarte, California, in an interview with Peers & Perspectives in Oncology. He highlighted the increased stress and anxiety for patients and staff, with many people evacuated and facing air quality issues. City of Hope implemented protocols, including evacuation plans, patient relocation, and resource distribution.